Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]
UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study
SHANGHAI, May 23, 2025 — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson’s disease. [Read more…]
Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development
MILPITAS, Calif. — Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) offer powerful tools for building off-the-shelf therapies by combining reduced immunogenicity, robust pluripotency, and genome engineering readiness. They are an isogenic match to the forthcoming GMP-grade versions to offer a seamless path from early research to clinical development. [Read more…]
CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease
Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly approved Phase 1 clinical trial for Alzheimer’s disease. The A3D trial has received authorization from the European Medicines Agency (EMA).
A3D is sponsored and promoted by CHU Toulouse, in collaboration with the Clinical Investigation Center in Biotherapy (CIC-BT), and coordinated by Dr Julien Delrieu, Principal Investigator of the study.
San Antonio healthcare services organization launches first-in-the-world mobile leukapheresis center supporting cell and gene therapies
New BBG Advanced Therapies vehicle will help bring lifesaving treatments to a wider patient base
San Antonio, Texas, May 06, 2025 – BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, has unveiled the first vehicle of its kind in the world, a mobile leukapheresis center designed to perform leukapheresis collections of starting materials for cell and gene therapies.
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 334
- Next Page »